A medical oncologist’s approach to immunotherapy for advanced renal tumors: Is nephrectomy indicated?

Current Urology Reports

Volumn 5, Issue 1, 2004, Pages 19-24

  Cooney, Matthew M ^a   Remick, Scot C ^b   Vogelzang, Nicholas J ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE

Author keywords

Clin Oncol; Kidney Cancer; Metastatic Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON;

HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; NEPHRECTOMY; ONCOLOGY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; INTERFERONS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; NEPHRECTOMY;

EID: 2142699517     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0006-x     Document Type: Article

References (48)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. J Clin 2000, 50:7–33. This reference gives the incidence of different malignancies in the United States.
2. Chow W, Devesa S, Warren JL, Fraumeni JF: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628–1631. DOI: 10.1001/jama.281.17.1628
3. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene: its role in renal carcinoma. JAMA 1995, 273:564–570. DOI: 10.1001/jama.273.7.564
4. Zbar B, Tory K, Merino M, et al.: Heriditary papillary renal cell carcinoma. J Urol 1994, 151:561–566.
5. Weirich G, Glenn G, Junker K, et al.: Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 1998, 160:335–340. DOI: 10.1016/S0022-5347(01)62888-X
6. Linehan WM, Lerman MI, Zbar B: Identification of the VHL gene: its role in renal carcinoma. JAMA 1995, 273:564–570. DOI: 10.1001/jama.273.7.564
7. Mellemgarrd A, Engholm G, McLaughlin JK, Olsen JH: Risk factors for renal cell carcinoma in Denmark: role of socioeconomic status tobacco use beverages and family history. Cancer Causes Control 1994, 5:105–113. DOI: 10.1007/BF01830256
8. Doublet JD, Peraldi MN, Gattegno B, et al.: Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997, 158:42–44. DOI: 10.1097/00005392-199707000-00012
9. Shapiro JA, Williams MA, Weiss NS: Body mass index and risk of renal cell carcinoma. Epidemiology 1999, 10:188–191. DOI: 10.1097/00001648-199903000-00019
10. Zambrano NR, Lubensky IA, Merino MJ, et al.: Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 1999, 162:1246–1258. DOI: 10.1016/S0022-5347(05)68259-6
11. Ro JY, Ayala AG, Sella A, et al.: Sarcomatoid renal cell carcinoma: clinicopathologic study of 42 cases. Cancer 1987, 59:516–526. DOI: 10.1002/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W
12. Skinner DG, Colvin RB, Vermillion CD, et al.: Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 1971, 28:1165–1177. DOI: 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G
13. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376.
14. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced kidney carcinoma. J Clin Oncol 1999, 17:2530–2540.
15. Motzer RJ, Bacik J, Murphy BA, et al.: Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289–296. The data on 463 patients in six clinical trials with advanced kidney cancer who were treated with interferon-α were reviewed. Five risk factors were found to be associated with a lower survival: low performance status, elevated lactate dehydrogenase, anemia, hypercalcemia, and time from diagnosis to start of interferon-α less than 1 year. These data can be used for risk stratification of phase 3 trials using interferon-α as the comparative treatment arm. DOI: 10.1200/JCO.20.1.289
16. Zisman A, Pantuck AJ, Dorey F, et al.: Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002, 20:1368–1374. This article reviews the University of California, Los Angeles (UCLA) data from 477 patients undergoing nephrectomy from 1989 through 1999. For the patients with metastatic disease, the significant variables in a multivariate analysis that were associated with a worse prognosis are a high Fuhrman’s grade, T stage 3 or 4, presence of lymph node involvement, and lack of immunotherapy treatment. These data present a mathematical model to estimate survival after radical nephrectomy in advanced kidney cancer. DOI: 10.1200/JCO.20.5.1368
17. Malhi S, Mekhail R, Jawde A, et al.: Factors associated with response and rapid progression in patients with metastatic renal cell cancer [Abstract 1611]. Proceedings of the American Society of Clinical Oncology. Chicago: May 31–June 3, 2003. This abstract, from the Cleveland Clinic Foundation (CCF), presents factors that are associated with a response to therapy in patients with advanced kidney cancer. These factors include prior nephrectomy, female gender, bony metastases, and absence of liver metastases.
18. Javidan J, Stricker HJ, Tamboli P, et al.: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999, 162:1277–1281. DOI: 10.1016/S0022-5347(05)68264-X
19. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969, 101:297–301.
20. Boxer RJ, Waisman J, Lieber MM, et al.: Renal carcinoma: computer analysis of 96 patients treated by nephrectomy. J Urol 1979, 122:598–601.
21. McClellan MM, Patel B, Choyke PL, et al.: Hypercalcemia in patients with metastatatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation. J Urol 1997, 158:733–739. DOI: 10.1016/S0022-5347(01)64303-9
22. deKernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978, 120:148–152.
23. Montie JE, Stewart BH, Straffon RA, et al.: The role of adjuvant nephrectomy in patients with metastastic renal cell carcinoma. J Urol 1977, 117:272–275.
24. Finke JH, Tubbs R, Connelly B, et al.: Tumor-infiltrating lymphocytes in patients with RCC. Ann NY Acad Sci 1988, 532:387–342. DOI: 10.1111/j.1749-6632.1988.tb36356.x
25. Kroemer G, Andreu JL, Gonzalo JA, et al.: Interleukin-2, autotolerance, and autoimmunity. Adv Immunol 1991, 50:147–235. DOI: 10.1016/S0065-2776(08)60825-1
26. Takeshita T, Asao H, Ohtani K, et al.: Cloning of the γ chain of the human IL-2 receptor. Science 1992, 257:379–382. DOI: 10.1126/science.1631559
27. Fyfe G, Fisher RI, Rosenberg SA, et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688–696.
28. Yang JC, Sherry RM, Steinberg SM, et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastastic renal cancer. J Clin Oncol 2003, 21:3127–3132. This three-arm randomized trial compares the response rates and overall survival of patients with advanced kidney cancer receiving high-dose IL-2, low-dose intravenous IL-2, or low-dose subcutaneous IL-2. The response rates ranged from 10% in the low-dose subcutaneous IL-2 to 21% in the high-dose IL-2 arm. There was no survival benefit seen with high-dose IL-2 compared with either low-dose arms. DOI: 10.1200/JCO.2003.02.122
29. Sleifer DT, Janssen RA, Buter J, et al.: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992, 10:1119–1123.
30. Motzer RJ, Mazumdar M, Bacik J, et al.: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:1928–1935. This is a retrospective analysis of 670 patients treated from 24 clinical trials at the Memorial Sloan Kettering Cancer Center with advanced kidney cancer. Patients treated with cytokines had a longer survival (range of 6 to 27 months based on risk category features) than those treated with chemotherapy. This article emphasizes the need for clinical investigation in this cancer because of the low proportion of long-term survivors.
31. Sato N, Nariuchi H, Tsuruoka N, et al.: Actions of TNF and INF-gamma on angiogenesis in vitro. J Invest Dermatol 1990, 95:85S-89S. DOI: 10.1111/1523-1747.ep12874809
32. Zhang ZJ, Muhr C, Wang JL: Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured menigioma cells. Anticancer Res 1996, 16:717–723.
33. Ji J, Si L, Fang W, Ling W: Interferon-gamma inhibits in situ expression of PDGF-beta mRNA by smooth muscle cells in injured rabbit arteries after transluminal balloon angioplasty. Clin Med J 2001, 114:139–142. This preclinical paper provides evidence that interferon-α (IFN-α) downregulates the in situ expression of PDGF-α mRNA in a rabbit vascular model.
34. Medical Research Council Collaborators: Interferon-α and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 1999, 353:14–17. DOI: 10.1016/S0140-6736(98)03544-2
35. Minasian LM, Motzer RJ, Gluck L, et al.: Interferon alpha-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow up. J Clin Oncol 1993, 11:1368–1375.
36. Porzsolt F, Messerer D, Hautmann R, et al.: Treatment of advanced renal cell cancer with recombinant interferonalpha as a single agent and in combination with medroxyprogesterone acetate: a randomized multicenter trial. J Cancer Res Clin Oncol 1988, 114:95–100. DOI: 10.1007/BF00390492
37. Fossa SD, Martinelli G, Otto U, et al.: Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III trial. Ann Oncol 1992, 4:301–305.
38. Pyrhonen S, Salminen E, Ruutu M, et al.: Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999, 17:2859–2867.
39. Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998, 338:1272–1278. DOI: 10.1056/NEJM199804303381805
40. Atkins MB, Sparano J, Fisher RI, et al.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell cancer. J Clin Oncol 1993, 11:661–670.
41. Jayson GC, Middleton M, Lee SM: A randomized phase II trial of interleukin-2 and interleukin-2 and interferon in advanced renal cancer. Br J Cancer 1998, 78:366–369.
42. Boccardo F, Rubagotti A, Canobbio L, et al.: Interleukin-2, interferon-alpha, and interleukin-2 plus interferon-alpha in renal cell carcinoma: a randomized phase II trial. Tumori 1998, 84:534–539.
43. Walther MM, Yang JC, Pass HI, et al.: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997, 158:1675–1678. DOI: 10.1016/S0022-5347(01)64091-6
44. Figlin RA, Pierce WC, Kaboo R, et al.: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2, and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997, 158:740–745. DOI: 10.1016/S0022-5347(01)64304-0
45. Fallick ML, McDermont DF, LaRock D, et al.: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691–1695. DOI: 10.1016/S0022-5347(01)64097-7
46. Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001, 358:966–970. This EORTC trial randomized a total of 85 patients with advanced kidney cancer (with an excellent performance status) to receive nephrectomy followed by interferon α-2b or interferon α-2b alone. In this small study, the time to progression (5 versus 3 months) and median duration of survival (17 versus 7 months) were significantly better in the patients undergoing a nephrectomy before immunotherapy. This trial provides a background to pursue a larger randomized trial to determine if nephrectomy before immunotherapy prolongs survival in patients with metastatic kidney cancer. DOI: 10.1016/S0140-6736(01)06103-7
47. Flannigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655–1659. This article presents the data from the Southwest Oncology Group’s (SWOG) 8949 trial that randomized 246 patients to nephrectomy followed by α-2b or interferon α-2b alone. The median survival was 11.1 months in the nephrectomy-plus-interferon arm versus 8.1 months (P = 0.05) in the interferon alone arm. This trial supports the use of nephrectomy before immunotherapy in patients with advanced kidney cancer who have an excellent PS (PS of 0 or 1). DOI: 10.1056/NEJMoa003013
48. Tannock IF: Removing the primary tumor after the cancer has spread. N Engl J Med 2001, 345:1699–1700. In this editorial, Tannock succinctly presents the main criticisms of the SWOG 8949 trial, which randomized patients to receive nephrectomy before interferon versus interferon alone. The incredibly slow accrual to this important trial raises the concern whether these results are applicable to the overall population of patients with advanced kidney cancer. It also is unclear why the patients who had a reduction in their tumor burden (via nephrectomy) essentially had the same response rate to interferon (3.3%) as those treated with interferon alone (3.6%). More patients in the interferon only arm had a worse PS (PS of 1) than those who were randomized to nephrectomy followed by immunotherapy. DOI: 10.1056/NEJM200112063452310